I agree with your summary. Imagin has developed extremely bright and high resolution optics they say are minimum 100X todays technology. They have also combined both screens into one image eliminating the doctors from having to switch back and forth during surgery. These two improvements alone are going to be significant for the doctors and patients. Reducing the image visualization time under 15min will be the icing on the cake. Imagin will be an attractive buy out candidate for several of the large bio-pharmas looking to update their own product offering.
One older analysis gave an estimated $3 to $4/sh valuation. With all three of Imagin's systems (i/Blue, i/Red, i/Vision) to consider, when fully functioning, that valuation may prove to be conservative.
News 
Market Data 
Discover 
